Literature DB >> 10322125

In vivo processing and antibiotic activity of microcin B17 analogs with varying ring content and altered bisheterocyclic sites.

R Sinha Roy1, N L Kelleher, J C Milne, C T Walsh.   

Abstract

BACKGROUND: The Escherichia coli peptide antibiotic microcin B17 (MccB17) contains four oxazole and four thiazole rings, and inhibits DNA gyrase. The role of individual and tandem pairs of heterocycles in bioactivity has not been determined previously.
RESULTS: The two tandem 4,2-bisheterocycles in MccB17 were varied by expression of MccB17 or mutants containing altered sequences at Gly39-Ser40-Cys41 or Gly54-Cys55-Ser56. A mixture of five-nine-ring MccB17 isoforms were separated and quantitated for antibiotic potency. Mutagenesis of the thiazole-oxazole pair significantly affected antibiotic activity compared with the upstream oxazole-thiazole, which might stabilize partially cyclized intermediates against proteolysis.
CONCLUSIONS: Enzymatic heterocyclization in native MccB17 occurs distributively. Antibiotic activity correlates with the number of rings and is differentially sensitive to both the location and the identity of the 4,2-tandem heterocycle pairs in MccB17. Such tandem heterocycles might be useful pharmacophores in combinatorial libraries.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10322125     DOI: 10.1016/s1074-5521(99)80076-3

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  15 in total

1.  In vitro characterization of DNA gyrase inhibition by microcin B17 analogs with altered bisheterocyclic sites.

Authors:  D B Zamble; D A Miller; J G Heddle; A Maxwell; C T Walsh; F Hollfelder
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

2.  Discovery of a widely distributed toxin biosynthetic gene cluster.

Authors:  Shaun W Lee; Douglas A Mitchell; Andrew L Markley; Mary E Hensler; David Gonzalez; Aaron Wohlrab; Pieter C Dorrestein; Victor Nizet; Jack E Dixon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-28       Impact factor: 11.205

3.  A major portion of DNA gyrase inhibitor microcin B17 undergoes an N,O-peptidyl shift during synthesis.

Authors:  Dmitry Ghilarov; Marina Serebryakova; Irina Shkundina; Konstantin Severinov
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

4.  The C-terminal part of microcin B is crucial for DNA gyrase inhibition and antibiotic uptake by sensitive cells.

Authors:  Irina Shkundina; Marina Serebryakova; Konstantin Severinov
Journal:  J Bacteriol       Date:  2014-02-21       Impact factor: 3.490

5.  Structure of microcin B-like compounds produced by Pseudomonas syringae and species specificity of their antibacterial action.

Authors:  Mikhail Metelev; Marina Serebryakova; Dmitry Ghilarov; Youfu Zhao; Konstantin Severinov
Journal:  J Bacteriol       Date:  2013-07-12       Impact factor: 3.490

6.  Insights into the mechanism of peptide cyclodehydrations achieved through the chemoenzymatic generation of amide derivatives.

Authors:  Kyle L Dunbar; Douglas A Mitchell
Journal:  J Am Chem Soc       Date:  2013-05-30       Impact factor: 15.419

Review 7.  YcaO-Dependent Posttranslational Amide Activation: Biosynthesis, Structure, and Function.

Authors:  Brandon J Burkhart; Christopher J Schwalen; Greg Mann; James H Naismith; Douglas A Mitchell
Journal:  Chem Rev       Date:  2017-03-03       Impact factor: 60.622

8.  An engineered lantibiotic synthetase that does not require a leader peptide on its substrate.

Authors:  Trent J Oman; Patrick J Knerr; Noah A Bindman; Juan E Velásquez; Wilfred A van der Donk
Journal:  J Am Chem Soc       Date:  2012-04-11       Impact factor: 15.419

Review 9.  Follow the leader: the use of leader peptides to guide natural product biosynthesis.

Authors:  Trent J Oman; Wilfred A van der Donk
Journal:  Nat Chem Biol       Date:  2010-01       Impact factor: 15.040

10.  Fragments of the bacterial toxin microcin B17 as gyrase poisons.

Authors:  Frédéric Collin; Robert E Thompson; Katrina A Jolliffe; Richard J Payne; Anthony Maxwell
Journal:  PLoS One       Date:  2013-04-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.